NR3C2 and heart failure: Management centers on immediate cessation of AAS use, which may lead to partial or complete reversal of cardiac dysfunction, particularly when identified early and accompanied by guideline-directed medical therapy for heart failure, including beta-blockers, RAAS inhibitors, mineralocorticoid receptor antagonists, and SGLT2 inhibitors.